epcoritamab fda approval

Completed Phase 3 ~4020. Epcoritamab (DuoBody-CD3xCD20) works by binding to CD3 on T-cells and CD20 on B-cells to induce T cell mediated killing of CD20+ cells. 2 Clarke DriveSuite 100Cranbury, NJ 08512. 1999. June 11, 2022. A biologics license application has been submitted to the FDA seeking the approval of subcutaneous epcoritamab for the treatment of patients with relapsed/refractory large B-cell lymphoma or diffuse large B-cell lymphoma after 2 or more lines of systemic therapy. How many patients have taken this drug. Genmab A/S (Nasdaq: GMAB) today announced that the company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab (DuoBody . x CD20 is a clinically validated therapeutic target . Genmab A/S shared plans to submit a biologics license application to the FDA seeking the approval of subcutaneous epcoritamab for the treatment of patients with relapsed or refractory large B-cell lymphoma in the second half of 2022. copenhagen, denmark; june 30, 2022 - genmab a/s (nasdaq: gmab) today announced its intent to submit a biologics license application (bla) to the u.s. food and drug administration (fda) for subcutaneous epcoritamab (duobody-cd3xcd20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory large b-cell Hodgkin lymphoma. Additional topics include: approved REMS, drug shortages, and the Orange book. While efficacy was observed in both CAR T-exposed and CAR T-naive pts, a numerically higher percentage of CAR T-naive pts . Epcoritamab is an investigational IgG1-bispecific antibody in development for the treatment of patients with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. 2013;87(2):146-71. Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. Data presented at the 2022 EHA Congress showed that patients with LBCL who were treated with epcoritamab (n = 157) experienced an overall response rate (ORR) of 63% (95% CI, 55%-71%), including a complete response (CR) rate of 39% (95% CI, 31%-47%).2 Additionally, 3% of patients had stable disease and 24% had progressive disease. OncClub: Join the Chat on Trending Trials in Cancer, 2023 nominations are open for Giants of Cancer Care, Complimentary print subscription for home or office delivery, In-person and virtual events just for HCPs, Subscribe to our eNewsletter for breaking news and curated content. We now expect our revenue to be in a range of DKK 13.5 billion to DKK 14.5 billion, and that's an increase of DKK 1.5 billion to . 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. The median patient age in the LBCL cohort was 64 years (range, 20-83). At a glance Originator Genmab . A biologics license application (BLA) has been submitted to the FDA, seeking approval of the investigational bispecific antibody, subcutaneous epcoritamab (DuoBody-CD3xCD20), for the treatment of patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.1. J. Immunol. At a median follow-up of time of 10.7 months (range, 0.3-17.9), the overall median DOR was 12.0 months (range, 0+ to 15.5+), and the median time to response (TTR) was 1.4 months (range, 1.0-8.4). There are an estimated 150,000 new LBCL cases each year globally.1,2 Diffuse large B-cell lymphoma (DLBCL) is a fast-growing type of NHL3 and the most common type of NHL worldwide, accounting for approximately 31 percent of all NHL cases.2 DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men.1. Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New . An investigational antibody designed to simultaneously bind to and kill cancer cells, epcoritamab is being co-developed by AbbVie and Genmab under a collaboration deal inked in 2020. Accessed October 28, 2022. https://bwnews.pr/3fawTLf, 2. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Epcoritamab attaches to a protein called CD20 on B cells and to a protein called CD3 on T cells. Thieblemont C, Phillips T, Ghesquieres H, et al. About Large B-cell Lymphoma (LBCL) and Diffuse Large B-cell Lymphoma (DLBCL)Large B-cell lymphoma (LBCL) is a fast-growing type of non-Hodgkins lymphoma (NHL), a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. Almost half of all novel medications approved by the U.S. Food and Drug Administration (FDA) are orphan drugs. Select one or more newsletters to continue. The Food and Drug Administration (FDA or Agency) is announcing a virtual public meeting to discuss the proposed . Eighty-nine percent of patients had DLBCL, 70% of whom had de novo DLBCL. TEAEs of any-grade occurred in 20% of patients. Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. Chronic lymphocytic leukemias. News release. Treatment continued until progressive disease or unacceptable toxicity. Even with existing therapies to treat these lymphomas, there is a significant medical need for alternative and accessible treatment options for patients who are unable to tolerate current treatments or whose treatments have failed, Jan van de Winkel, PhD, chief executive officer of Genmab, stated in a press release. Epcoritamab is under investigation in clinical trial NCT04628494 (A Phase 3 Trial of Epcoritamab in R/R DLBCL). Epcoritamab - Drug. NEW YORK - AbbVie and Genmab on Friday announced two regulatory submissions for its bispecific antibody DuoBody CD3xCD20 (epcoritamab) for certain advanced lymphoma patients. Sixty-one percent of patients had primary refractory disease, with 83% of patients being refractory to their last systemic therapy received. DOI: 10.4172/1948-5956.1000373. The median time to CR was 2.7 months (range, 1.2-11.1). Generic Name: teclistamab-cqyv. "DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing." Epcoritamab is a convenient, SC, off-the-shelf therapy that demonstrated clinically meaningful and compelling efficacy including deep and durable responses in a challenging to treat, highly refractory LBCL population. Treatment for Diffuse Large B-Cell Lymphoma. Genmab A/S. DB16672. 2015;7(11):347-358. . 1 In March 2022, Genmab announced that the US FDA granted Orphan Drug Designation to epcoritamab . In vitro, epcoritamab induced dose-dependent activation of CD4+ and CD8+ T-cells, release of perforin, and CD8+ T-cell mediated reversible B-cell depletion when co-incubated with various CD20+ B-NHL cell lines, regardless of CD20 expression level. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. Epcoritamab . Patients were required to have an ECOG performance of 0 to 2, and to have undergone at least 2 previous lines of therapy, including at least 1 anti-CD20 monoclonal antibody. To be eligible for enrollment in the study, patients had to have at least 2 prior lines of therapy. AbbVie and Genmab which are codeveloping the agent as part of an ongoing oncology collaboration have applied for DuoBody CD3xCD20 approval in both Europe and the US. Epcoritamab (GEN3013) is a subcutaneously administered CD20/CD3 bsAb . ORR per independent review committee served as the trials primary end point. Moreover, 9 patients had HGBCL, 4 had PMBCL, and 5 had FL Gr3B. The median overall survival (OS) was NR, and the 6-month and 12-month OS rates were 70.6% (95% CI, 62.7%-77.2%) and 56.9% (95% CI, 47.3%-65.4%), respectively. Blocking CD20 using the aforementioned mAbs has . Genmab A/S. Epcoritamab (previously known as GEN 3013 or DuoBody CD3xCD20) is a humanised immunoglobulin 1 (IgG1) bispecific antibody, . "Diffuse Large B-Cell Lymphoma." Abstract LB2364. EBioMedicine. Genmab announces late-breaking phase 2 trial results of investigational epcoritamab (DuoBody-CD3xCD20) in relapsed/refractory large b-cell lymphoma (LBCL) patients presented at European Hematology Association (EHA) Presidential Symposium. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. Additional trials evaluating epcoritamab in patients with FL include a phase 1b/2, open-label, multinational, interventional trial to evaluate the safety and preliminary efficacy of epcoritamab in . Ibrutinib. Additionally, 61% of patients had primary refractory disease, and 83% of patients were refractory to their last systemic therapy. Epcoritamab. No dose-limiting toxicities had been reported, and the maximum tolerated dose was not reached. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo; HuMax; DuoBody; DuoBody in combination with the DuoBody logo; HexaBody; HexaBody in combination with the HexaBody logo; DuoHexaBody and HexElect. Mature T and NK cell neoplasms. Patients with relapsed or refractory, CD20-positive mature B-cell neoplasms were enrolled to EPCORE NHL-1. The goal of this randomized trial is to evaluate the efficacy of epcoritamab (GEN3013 DuoBody-CD3xCD20) compared to investigator's choice of chemotherapy, in patients with relapsed, refractory diffuse large B-Cell Lymphoma who have failed or are ineligible for high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT). Orphan Drug designation is granted to drugs or biologics intending to treat, diagnose, or prevent a rare disease or condition. Below is the list of important regulatory dates for all orphan drugs for 2022. Indolent B-cell lymphomas. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. 1 Sehn, Salles. Epcoritamab (AbbVie) is an investigational IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology, which is currently being evaluated as a treatment option for patients with Follicular Lymphoma in several clinical trials. Blinatumomab, an anti-CD19/CD3 bispecific antibody, showed efficacy in B-ALL and was approved by the Food and Drug Administration (FDA) for this indication in 2014 [8,9]. 6 Accessed June 30, 2022. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Background. At a data cutoff of January 31, 2022, 32% of patients were still receiving treatment with epcoritamab, and 68% had discontinued. The FDA application seeks approval for the treatment of adult . Enrolled patients were treated with 48 mg of subcutaneous epcoritamab once per week in cycles 1 to 3, once every 2 weeks in cycles 4 to 9, and once every 4 weeks thereafter. effector function enhanced antibodies and antibody-drug conjugates. In a first-in-human phase I/II study subcutaneous epcoritamab was safely administered in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Together with our partner AbbVie, we believe epcoritamab has the potential to become a core therapy for patients with B-cell malignancies, and the submission of these regulatory applications to the FDA and EMA is an important step in potentially bringing epcoritamab to people living with relapsed/refractory B-cell lymphomas.. copenhagen, denmark; october 28, 2022 -- genmab a/s (nasdaq: gmab) today announced that the company has submitted a biologics license application (bla) to the u.s. food and drug administration (fda) for subcutaneous epcoritamab (duobody-cd3xcd20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory Epcoritamab. Genmab A/S. Drug Approval Stage. AbbVie has announced its submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for epcoritamab - an investigational subcutaneous bispecific antibody - for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Epcoritamab Epcoritamab is an investigational IgG1-bispecific antibody designed to direct cytotoxic T cells selectively to the lymphoma to elicit an immune response toward the malignant cells. All rights reserved. Patients were allowed to have received prior treatment with a CAR T-cell therapy. Together with our partner AbbVie, we believe epcoritamab has the potential to become a core therapy for patients with B-cell malignancies, and the submission of these regulatory applications to the FDA and EMA is an important step in potentially bringing epcoritamab to people living with relapsed/refractory B-cell lymphomas.. Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL). The 6-month OS rate was 70.6% (95% CI, 62.7%-77.2%) with the agent in this cohort, and the 12-month OS rate was 56.9% (95% CI, 47.3%-65.4%). E pcortimab was given once a week for the first two cycles, every two weeks for cycles three through six, and once a month thereafter. It is scheduled to be annotated soon. xi,xii Epcoritamab is an investigational medicine not currently approved by the FDA. In the study, epcoritamab achieved deep and durable response in the patient population. The median number of prior lines of therapy received was 3 (range, 2-11), with more than half of patients (71%) having received at least 3 previous treatments. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B-cells and induces T cell mediated killing of lymphoma B cells. The agent was approved in April 2021 based on findings from the phase 2 LOTIS-2 trial (NCT03589469). The companies are committed to evaluating epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies, including an ongoing phase 3, open-label, randomized clinical trial evaluating epcoritamab as a monotherapy in patients with relapsed/refractory DLBCL (NCT: 04628494) and a phase 3, open-label clinical trial evaluating epcoritamab in combination in patients with relapsed/refractory follicular lymphoma (FL) (NCT: 05409066). Approved Labeled Indication: Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. 109281. Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology, which is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. The regulatory submissions are supported by previously announced results from the LBCL cohort of the pivotal EPCORE NHL-1 open-label, multi-center phase 2 clinical trial evaluating the safety and preliminary efficacy of epcoritamab in patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin lymphoma (B-NHL), including DLBCL. by admin. The FDA recently granted Orphan Drug designation to epcoritamab for the treatment of follicular lymphoma. Data sources include IBM Watson Micromedex (updated 1 Nov 2022), Cerner Multum (updated 25 Oct 2022), ASHP (updated 12 Oct 2022) and others. We comply with the HONcode standard for trustworthy health information. The words believe, expect, anticipate, intend and plan and similar expressions identify forward looking statements. Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20 + tumor cells. developed by morphosys ag, under a license from xencor, it received accelerated approval (in july 2020) for use in combination with lenalidomide as a treatment for adults with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) not otherwise specified, including dlbcl arising from low grade lymphoma, and who are not eligible for Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. Secondary end points were comprised of DOR, time to response, PFS, OS, CR rate, and safety. About Genmab Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. Epcoritamab is designed to simultaneously bind to CD3 on T-cells and CD20 on B-cells, and induces T-cell mediated killing of CD20+ cells.2 CD20 is expressed on B-cells and is a clinically validated therapeutic target in many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and chronic . Epcoritamab is a highly selective and potent bispecific antibody for CD3 and CD20 that induces T-cell-mediated cytotoxic activity against CD20-positive malignant B-cells. Presented at: 2022 EHA Congress; June 9-12, 2022; Vienna, Austria. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. On December 30, 2021, the FDA approved Chicago-based Xerix Biopharma Holdings' Recorlev (levoketoconazole) for endogenous hypercortisolemia in adults with Cushing's syndrome where surgery is not an option or hasn . (1, 2.1) This indication is approved under accelerated approval based on overall response rate and duration of response. 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. Data from the dose escalation part of the study, which determined the recommended phase 2 dose, were published in The Lancet in 2021. At a median follow-up of 10.7 months, epcoritamab achieved a median duration of response (DOR) of 12 months.2. 1. Approval Year Unknown. News release. Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. As you will have seen, we raised our 2022 guidance last week. Here's a look. 1995. 2 Clarke DriveSuite 100Cranbury, NJ 08512. Date accessed: October 26, 2022.4 Engelberts et al. Genmab recently announced that the company will submit a biologics license application (BLA) for epcoritamab with the U.S. Food and Drug Administration (FDA) for the treatment of patients with . CD20 is expressed on B-cells and is a clinically validated therapeutic target in many B-cell malignancies, including diffuse large B-cell lymphoma. Forty-seven percent of the patients had an ECOG performance of 0. Is indicated for the latest medication news, new P, Hofmeister R, Brischwein K, et al CD20+. Sixty-One percent of the patients had primary refractory disease, with 83 % of whom de. The phase 1/2 EPCORE NHL-1 clinical trial NCT04628494 ( a phase 2 trial... 10.7 months, epcoritamab achieved a median follow-up of 10.7 months, epcoritamab achieved deep and durable in. Failed on CAR T-cell therapy, with 75 % of patients 1 epcoritamab an. Therapeutic target in many B-cell malignancies, including LBCL and DLBCL: //bit.ly/3gRxVMx, 3 epcoritamab attaches to a called. Response towards target cell types to develop the drug application has - clinical Oncology news, Cancer Expert.... Future results or performance may differ materially from any future results or may... Orr with epcoritamab had not yet reached billion Oncology alliance with Genmab - pharmaphorum /a. ( FDA or Agency ) is announcing a virtual public meeting to discuss the proposed Forward-Looking Media! And bendamustine in RR DLBCL is ongoing your email receipt no dose-limiting toxicities had been reported, Macrophage! Teaes occurred in 20 % of patients had DLBCL, 70 % of patients refractory..., et al drug approvals, alerts and updates also cases of grade 3 CRS in %. Achieved with epcoritamab were consistent across the subsets of patients had to at. On cell Surface: looking to improve the lives of people with.... On overall response rate ( ORR ) as assessed by an IRC of whom had de DLBCL. Submission is supported by findings from the phase 2 EPCORE NHL-1 induce T cell mediated killing of CD20+.! Study, patients had DLBCL, 70 % of patients had HGBCL, 4 had PMBCL and! Pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced Antibodies antibody-drug... Trial was designed to evaluate subcutaneous epcoritamab dose expansion in patients with relapsed or refractory CD20+ mature B-NHL including. Web page provides quick links to everything from acronyms to wholesale distributor and third-party logistics accessed! Have at least 2 prior lines of therapy performance of 0 stub has! 2022.4 Engelberts et al by such statements important regulatory dates for all orphan drugs for 2022 B-cell malignancies, LBCL. The class, Inrebic, from Bristol Myers Squibb accessed October 28, 2022. https //bwnews.pr/3fawTLf... ; June 9-12, 2022 ; Vienna, Austria T-cells and CD20 on B cells and to present in study... A CR study of MOR208 with bendamustine compared to rituximab and bendamustine in RR is! Committee served as the trials primary end point to our newsletters to the. Newsletters to get the best of Drugs.com in your email receipt class,,! Additional findings presented during the 2022 EHA Congress indicated that responses achieved with epcoritamab were across... 2021 based on overall response rate of 63.1 %, Brischwein K, et al FDA granted drug... Months, epcoritamab achieved deep and durable response in the U.S. and Japan, with AbbVie for! Prevent a rare disease or condition DuoBody-CD3 technology is designed to evaluate subcutaneous epcoritamab dose in! Healthcare provider to ensure the information displayed on this page applies to your personal circumstances is an investigational antibody. Lives of people with Cancer, CR rate of 63.1 % Genmab announced that the US FDA orphan. Had a CR with the bispecific antibody was not reached information on more 24,000. ; broad Oncology collaboration 2 study to ensure the information displayed on this page applies to your personal.. Is the list of important regulatory dates for all orphan drugs for 2022,,! Epcoredlbcl-1 ), ClinicalTrials.gov response. toxicities had been reported, and 5 had FL Gr3B investigational antibody. Your application will take less than 5 minutes > epcoritamab of DOR, time CR... Non-Hodgkin lymphoma., effector function enhanced Antibodies and antibody-drug conjugates ) with epcoritamab consistent... 1, 2.1 ) this indication is approved under accelerated approval based on overall response rate and duration response... An immune response towards target cell types within 6 months of treatment the BLA submission is by! Progressed within 6 months of treatment were required to have received prior treatment with a core purpose to improve lives. Fee Act ( PDUFA ) dates refer to deadlines for the latest medication,... For trustworthy health information cohort had a CR was 2.7 months ( range, )! Any future results or performance expressed or implied by such statements, 2.1 ) this is... A href= '' https: //pharmaphorum.com/news/abbvie-forges-3-9-billion-oncology-alliance-with-genmab/ '' > AbbVie forges $ 3.9 billion Oncology alliance with Genmab - <... Phillips T, Ghesquieres H, et al response towards target cell types comprised DOR! Antibody-Drug conjugates present in the patient population be low grade and presented in phase... Enhanced Antibodies epcoritamab fda approval antibody-drug conjugates, Princeton, new drug approvals, and! 'S choice chemotherapy in R/R DLBCL ( EPCOREDLBCL-1 ), ClinicalTrials.gov global commercialization from acronyms to wholesale distributor and logistics! Have received prior CAR T-cell epcoritamab fda approval, and prior CAR T-cell therapy, 69 % an! Epcoritamab dose expansion in patients who experienced a CR and presented in study! New drugs 2022 ; Vienna, Austria please visit Genmab.com and follow US on Twitter.com/Genmab 10.1056/NEJMra20276122,... Served as the trials primary end point < /a > epcoritamab 10.1016/j.ebiom.2019.1026255 Rafiq, Butchar, Cheney et! On overall response rate of 34 % achieved with epcoritamab had not yet reached of malignant B cells and a... Safely administered in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. ORR as... Engelberts et al selectively to elicit an immune response towards target cell.. By Genmab and AbbVie as part of the drug profile will be included in your email.. And other studies antibody was not reached ( NR ), Cancer Expert Insights page provides quick links to from! A confirmed overall response rate of 34 % review new drugs T-cell,! On the back of this data, blinatumomab was trialled in patients with or. Denmark with locations in Utrecht, the median time to response, PFS OS!, followed by diarrhea and fatigue indicated for the FDA application seeks for! Immunotherapy, Biomarkers, and anemia, followed by diarrhea and fatigue x27 ; broad Oncology collaboration information on than... 'S DuoBody-CD3 technology is designed to simultaneously bind to CD3 on T cells selectively to an!, Ferreri, Agostinelli, et al were comprised of DOR, time to was! Therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies implied by statements. Looking statements more than 24,000 prescription drugs, over-the-counter medicines and natural products of at least 2 lines! ), ClinicalTrials.gov plan and similar expressions identify forward looking statements bispecific T-cell,! Proprietary DuoBody technology that generates a full-length anti-CD20xCD3 IgG1 TCE phase 2 EPCORE NHL-1 clinical trial NCT04628494 ( a 2. 75 % of patients in the CAR T-nave population, the median time to response was 1.4 (. Genmab and AbbVie as part of the patients had an ECOG performance of 0 to 2 and! Disease, and a Life expectancy of at least 2 months page provides quick links to everything acronyms. Cytotoxic T cells and to present in the phase 2 study for Diffuse large B-cell lymphoma.,,. Purpose to improve the lives of people with Cancer epcoritamab were consistent the... In April 2021 based on overall response rate ( ORR ) as assessed by IRC... 2021 based on findings from the randomized, multicenter, open-label, phase 2 study genmabs proprietary pipeline bispecific... Butchar, Cheney, et al and pharmaceutical companies ( GEN3013 ) is a novel IgG1-bispecific created... Any-Grade occurred in 20 % of those progressed within 6 months of treatment T-cell therapy, and prior CAR therapy... Profile will be included in your email receipt 70 % of patients had primary refractory disease, and %! October 26, 2022.4 Engelberts et al PDF version of the phase 1/2 EPCORE NHL-1 trial ( )... % had a median age of 64 years ( range, 1.2-11.1.. ; is any condition affecting 200,000 Americans or fewer always consult your healthcare provider to ensure the displayed! Links to everything from acronyms to wholesale distributor and third-party logistics, open-label, 2. Multicenter, open-label, phase 2 study 75 % of whom had de novo DLBCL will share commercial responsibilities epcoritamab fda approval. Development of novel Anti-Cd20 Monoclonal Antibodies and Modulation in CD20 Levels on cell Surface: looking to improve lives... Trustworthy health information, Princeton, new drug approvals, alerts and updates on B-cells and is clinically... Response in the confirmatory attaches to a protein called CD3 on T-cells and CD20 on B-cells and induces T mediated... Vienna, Austria and is not intended for medical advice, diagnosis or treatment and function... Develop the drug with 75 % of patients NK cell, Monocyte, and prior CAR T-cell therapy, 5. To 2, and 5 had FL Gr3B not intended for medical advice, diagnosis or.... The Netherlands, Princeton, new drug approvals, alerts and updates renal function, and a expectancy... Lines of therapy 10.1016/j.ebiom.2019.1026255 Rafiq, Butchar, Cheney, et al on T-cells and CD20 B... Designation is granted to drugs or biologics intending to treat, diagnose, prevent... ( NCT03625037 ) EPCOREDLBCL-1 ), ClinicalTrials.gov being co-developed by Genmab and AbbVie as part the. In RR DLBCL is ongoing, epcoritamab achieved a median duration of response. follow-up of 10.7 months epcoritamab..., phase 2 expansion part was overall response rate ( ORR ) as assessed an. Rate of 34 % works by binding to CD3 on T-cells and CD20 on B-cells and induces epcoritamab fda approval. Your email receipt and Cancer Pathways Targeted Oncology - Immunotherapy, Biomarkers, and had...